In clinical trials, a sham is a procedure or device that looks the same and feels the same as an active treatment being tested but doesn’t actually do anything.

Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.

Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).

GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.

Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.

The International Union of Pure and Applied Chemistry (IUPAC) is a non-governmental organization dedicated to promoting chemistry-related activities.

The European Commission has approved STADA and Alvotech's biosimilar Uzpruvo® (AVT04), similar to Stelara® (ustekinumab), for marketing.

Kymera Therapeutics began their Phase 2 ADVANTA study for KT-474 in AD on Dec 7, 2023, prompting a $15M milestone payment from Sanofi.

Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.

The drug packaging box sent to the subject will be returned to the investigator by the subject after the end of the trial.

Corbus Pharmaceuticals Holdings, Inc., focused on precision oncology, announced FDA approval for its CRB-601 drug application.